
Blackstone has announced that funds managed by Blackstone Life Sciences will provide US$750 million in development funding to Johnson & Johnson to support the Phase 3 clinical development of OLN324, an investigational therapy for serious retinal vascular diseases. Specifically, Blackstone will finance the Phase 3 clinical program of OLN324, including wet age-related macular degeneration and diabetic macular edema, following the expected closing of the acquisition of Ollin Biosciences, Inc.
Latham & Watkins LLP represented the client in the transaction with a healthcare finance team led by Bay Area partners Todd Trattner and Haim Zaltzman, with associates William Lane and William Jackson. Advice was also provided on tax matters by Los Angeles partner Eric Cho, with associate Sam Yang; on intellectual property matters by New York partner Rachel Blitzer and Washington, D.C. partner Reba Rabenstein, with associate Drew Roberts; and on healthcare regulatory matters by Washington, D.C. counsel Chad Jennings.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record

